HPV Associated Disorders Market - Strategic Insights and Forecasts (2025-2030)

Description

HPV Associated Disorders Market Size:

The HPV-associated disorders market is expected to witness significant growth during the forecasted period.

To learn more about this report, request a free sample copy

More than 100 viruses make up the human papillomavirus family, 14 of which can lead to cancer. HPV is the reason for almost all occurrences of cervical cancer. In women living in less developed areas, cervical cancer is the second most prevalent kind, with an estimated 6,04,000 new cases and 3342,000 deaths every year.

Cervical cancer is six times more common in women living with HIV than in those without the virus, and HIV is thought to be the cause of 5% of cervical cancer occurrences. Furthermore, younger women are disproportionately affected by HIV-related cervical cancer in all parts of the world.

To diagnose HPV-associated disorders, there are a few tests, such as the vinegar (acetic acid) solution test, where genital regions infected with HPV become white when a vinegar solution is administered to them. Pap Test, for laboratory analysis, the doctor takes a sample of cells from your vagina or cervix, which can identify irregularities that may result in cancer. DNA Tests can identify the DNA of high-risk HPV strains that have been connected to genital malignancies using cells taken from the cervix. For women 30 years of age and above, it is advised to undergo the Pap test.

HPV Associated Disorders Market Growth Drivers:

• Growing prevalence of cervical cancer

The World Health Organization (WHO) Factsheet states that palliative care is a crucial component of comprehensive cervical cancer control, in addition to primary prevention measures like HPV vaccination, secondary prevention measures like pre-cancerous lesion screening and treatment, and tertiary prevention measures like diagnosis and treatment of invasive cervical cancer. Such health authority rules contribute to the HPV-associated disorders market expansion.

Similar to this, the Australian Government has pledged USD 5.8 million to assist the World Health Organization's (WHO) announcement of a worldwide commitment to eradicate cervical cancer in November 2021. The National Cervical Screening Program urges women to have a fast test for HPV, a common virus that nearly invariably leads to cervical cancer, every five years.

• Government initiatives for the treatment of HPV-associated disorders

Governments around the globe are focusing on various initiatives for the treatment of HPV-associated disorders. For instance, to meet the 2030 SDGs, the Indonesian government is dedicated to reducing morbidity, mortality, and disability brought on by illnesses that may be prevented by vaccination. The Ministry of Health has made it a priority to improve health services in the nation by expanding and strengthening health services to concentrate more on preventive promotive efforts.

One way to achieve this is by adding new vaccines to the national immunization program, such as the HPV vaccine. The government is dedicated to creating a more robust and inventive system. Furthermore, the WHO Strategic Advisory Group of Experts on Immunisation (SAGE) met in April 2023 and reviewed the mounting evidence showing single-dose schedules are just as effective as two- or three-dose regimens.

• Growing preference for HPV tests

HPV tests outperform other screening techniques, such as pap smears and visual inspection with acetic acid (VIA), allowing for the identification of more people who require treatment. Due to the greater quality, patients who obtain a negative HPV test result can frequently wait longer between tests, which is advantageous for both them and the healthcare system. A few HPV tests even provide patients the option to collect their sample with a simple swab, giving women the option to get tested without having a healthcare provider do a pelvic exam.

Numerous HPV tests are even performed using the same hardware as COVID-19 PCR and HIV assays, among others, allowing them to be integrated into current laboratory systems. Such technologies can help remove more obstacles to services and make it easier for public health initiatives to reach the aim of 70% screening.

• Growing initiatives by healthcare organizations

The list of prequalified tests for human papillomavirus (HPV) now includes a fourth test, according to WHO. While the majority of HPV infections go away on their own, some high-risk varieties can result in cervical cancer. Cervical cancer screening always includes testing for HPV infection. The prequalification (PQ) program for in vitro diagnostics (IVDs) run by the WHO assesses a variety of tests, including those used to screen for cervical cancer and identify high-risk HPV genotypes.

The inclusion of yet another item on the PQ list broadens the selection of high-performance tests that nations may access, especially when governments, UN organizations, or other partners depend on the WHO program to facilitate their purchase.

• Rising demand for HPV vaccinations

Throughout the anticipated period, the demand for HPV vaccinations is anticipated to be the main factor driving the global HPV-associated disorders industry potential due to the rising prevalence of HPV-related disorders. Bivalent, quadrivalent, and nonavalent vaccinations are the kinds of vaccinations available on the market.

The three vaccinations are all quite effective at protecting against the 16 and 18 viruses, which represent 70% of cervical cancer cases.  The regulatory authorities' acceptance of the new vaccine increases the accessibility of vaccines for immunization or vaccination, which is projected to hasten the HPV-associated disorders market expansion.

HPV Associated Disorders Market Geographical Outlook:

• Skeletal dysplasia market in the Asia Pacific region is anticipated to grow steadily.

The HPV-associated disorders market in the Asia Pacific is anticipated to be fueled by the presence of major HPV-associated disorders industry players and growth in various initiatives in the region. For instance, in October 2022, on the last day of the 73rd session of the WHO Regional Committee for the Western Pacific, delegates approved frameworks designed to prevent and control cervical cancer, reach the unreached, and advance the best possible mental and physical health for everyone in the region.

Over 95% of occurrences of cervical cancer are associated with high-risk human papillomavirus (HPV) infection. Persistent HPV infections can lead to cervical cancer in women, even though the majority of infections clear up on their own and have no symptoms. According to estimates by the WHO, 145,700 women in the Western Pacific Region received a cervical cancer diagnosis in 2020, and 74,900 of them lost their lives to the most treatable and avoidable illness.

HPV Associated Disorders Market Key Developments:

• November 2025: Landmark Clinical Trial Data Supports Cell Therapy as Breakthrough for HPV-Associated Cancers. New data presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting unveiled positive Phase 2 trial results for a T cell receptor (TCR)-T cell therapy targeting metastatic cancers associated with Human Papillomavirus (HPV). The findings suggest that one-time cell therapies could offer durable responses and fundamentally reshape the treatment landscape for difficult-to-treat HPV-associated epithelial cancers (e.g., head and neck, cervical, anal).
• November 2025: WHO Confirms Global Goal Met to Vaccinate 86 Million Girls Against HPV by End of 2025. The World Health Organization (WHO) and Gavi, the Vaccine Alliance, confirmed that global efforts to accelerate HPV vaccination campaigns have met the ambitious goal of reaching 86 million girls by the end of 2025. This milestone, supported by numerous countries adopting the single-dose schedule, accelerates progress toward eliminating cervical cancer as a public health problem.
• May 2025: New Liquid Biopsy Blood Test Shows Superior Accuracy for Detecting HPV-Associated Head and Neck Cancers. Researchers from Mass General Brigham published a study on HPV-DeepSeek, a new liquid biopsy blood test that demonstrated 99% sensitivity and 99% specificity for diagnosing HPV-associated head and neck cancers, significantly outperforming current standard-of-care methods. This breakthrough offers the potential to screen for these cancers years before patients develop symptoms, enabling earlier and less invasive treatment.
• April 2025: Australia Updates National Cervical Screening Guidelines to Include HPV Self-Collection and Annual Testing. New clinical guidelines for the National Cervical Screening Program (NCSP) took effect, incorporating the option for self-collected HPV tests and changing post-treatment management for high-grade lesions (HSIL) to annual HPV tests until two consecutive tests are negative. This policy shift prioritizes user convenience and less invasive molecular testing to improve screening coverage and compliance.

HPV Associated Disorders Market Scope:

HPV Associated Disorders Market Segmentation:

• By Indication
  • CIN
  • Cervical Cancer
  • AIN
  • Anal Cancer
  • Others
• By Therapy
  • Prevention
  • Treatment
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

Table Of Contents

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. HPV ASSOCIATED DISORDERS MARKET BY INDICATION

5.1. Introduction

5.2. CIN

5.2.1. Market opportunities and trends

5.2.2. Growth prospects

5.2.3. Geographic lucrativeness 

5.3. Cervical Cancer

5.3.1. Market opportunities and trends

5.3.2. Growth prospects

5.3.3. Geographic lucrativeness 

5.4. AIN

5.4.1. Market opportunities and trends

5.4.2. Growth prospects

5.4.3. Geographic lucrativeness 

5.5. Anal Cancer

5.5.1. Market opportunities and trends

5.5.2. Growth prospects

5.5.3. Geographic lucrativeness 

5.6. Others

5.6.1. Market opportunities and trends

5.6.2. Growth prospects

5.6.3. Geographic lucrativeness 

6. HPV ASSOCIATED DISORDERS MARKET BY THERAPY

6.1. Introduction

6.2. Prevention

6.2.1. Market opportunities and trends

6.2.2. Growth prospects

6.2.3. Geographic lucrativeness 

6.3. Treatment

6.3.1. Market opportunities and trends

6.3.2. Growth prospects

6.3.3. Geographic lucrativeness 

7. HPV ASSOCIATED DISORDERS MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital Pharmacies

7.2.1. Market opportunities and trends

7.2.2. Growth prospects

7.2.3. Geographic lucrativeness 

7.3. Retail Pharmacies

7.3.1. Market opportunities and trends

7.3.2. Growth prospects

7.3.3. Geographic lucrativeness 

7.4. Online Pharmacies

7.4.1. Market opportunities and trends

7.4.2. Growth prospects

7.4.3. Geographic lucrativeness 

8. HPV ASSOCIATED DISORDERS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Indication

8.2.2. By Therapy

8.2.3. By Distribution Channel

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Trends and Opportunities

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Trends and Opportunities

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Trends and Opportunities

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Indication

8.3.2. By Therapy

8.3.3. By Distribution Channel

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.1.1. Market Trends and Opportunities

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Trends and Opportunities

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Trends and Opportunities

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Indication

8.4.2. By Therapy

8.4.3. By Distribution Channel

8.4.4. By Country

8.4.4.1. Germany

8.4.4.1.1. Market Trends and Opportunities

8.4.4.1.2. Growth Prospects

8.4.4.2. France

8.4.4.2.1. Market Trends and Opportunities

8.4.4.2.2. Growth Prospects

8.4.4.3. UK

8.4.4.3.1. Market Trends and Opportunities

8.4.4.3.2. Growth Prospects

8.4.4.4. Spain

8.4.4.4.1. Market Trends and Opportunities

8.4.4.4.2. Growth Prospects

8.4.4.5. Others

8.4.4.5.1. Market Trends and Opportunities

8.4.4.5.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Indication

8.5.2. By Therapy

8.5.3. By Distribution Channel

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Trends and Opportunities

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Trends and Opportunities

8.5.4.2.2. Growth Prospects

8.5.4.3. Israel

8.5.4.3.1. Market Trends and Opportunities

8.5.4.3.2. Growth Prospects  

8.5.4.4. Others

8.5.4.4.1. Market Trends and Opportunities

8.5.4.4.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Indication

8.6.2. By Therapy

8.6.3. By Distribution Channel

8.6.4. By Country

8.6.4.1. China

8.6.4.1.1. Market Trends and Opportunities

8.6.4.1.2. Growth Prospects

8.6.4.2. Japan

8.6.4.2.1. Market Trends and Opportunities

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Trends and Opportunities

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Trends and Opportunities

8.6.4.4.2. Growth Prospects

8.6.4.5. Indonesia

8.6.4.5.1. Market Trends and Opportunities

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Trends and Opportunities

8.6.4.6.2. Growth Prospects

8.6.4.7. Others

8.6.4.7.1. Market Trends and Opportunities

8.6.4.7.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisition, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Merck Vaccines

10.2. PapiVax Biotech

10.3. Cleveland Clinic

10.4. Johns Hopkins Medicine

10.5. Advaxis

10.6. Kovina Therapeutics

10.7. Gavi

10.8. The Native Antigen Company

10.9. Eurogin

10.10. Queensland Health

Companies Profiled

Merck Vaccines

PapiVax Biotech

Cleveland Clinic

Johns Hopkins Medicine

Advaxis

Kovina Therapeutics

Gavi

The Native Antigen Company

Eurogin

Queensland Health

Related Reports